Raloxifene improves verbal memory in late postmenopausal women: A randomized, double-blind, placebo-controlled trial

Menopause

Volumn 17, Issue 2, 2010, Pages 309-314

  Jacobsen, Didy E ^a   Samson, Monique M ^a   Emmelot Vonk, Marielle H ^a   Verhaar, Harald J J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Postmenopausal women; Raloxifene; Verbal memory

Indexed keywords

PLACEBO; RALOXIFENE;

AGED; ANXIETY; ARM DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FLUSHING; GERIATRIC DEPRESSION SCALE; HEADACHE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MASTALGIA; MENTAL PERFORMANCE; MENTAL TEST; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; STATE TRAIT ANXIETY INVENTORY; VERBAL MEMORY; WOMEN'S HEALTH; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANXIETY; COGNITION; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEMORY; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 77949399853     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181bd54df     Document Type: Article

References (36)

1. Henderson VW. Cognitive changes after menopause: influence of estrogen. Clin Obstet Gynecol 2008;51:618-626.
2. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA 2001;285:1489-1499.
3. Zola-Morgan S, Squire L. Neuroanatomy of memory. Annu Rev Neurosci 1993;16:547-563.
4. Frisk V, Milner B. The role of left hippocampal region in the acquisition and retention of story content. Neuropsychologica 1990;28:349-359.
5. Weiland N, Orikasa C, Hayashi S, McEwen B. Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J Comp Neurol 1997;388:603-612.
6. Register T, Shively C, Lewis C. Expression of estrogen receptor > and A transcripts in female monkey hippocampus and hypothalamus. Brain Res 1998;788:320-322.
7. Shughrue P, Lane M, Merchentaler I. Comparative distribution of estrogen receptor-> and-A mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-525.
8. Hampson E. Estrogen-related variation in human spatial and articulatory motor skills. Psychoneuroendocrinology 1990;15:97-111.
9. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendo-crinology 1988;13:345-357.
10. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
11. Ott SM, Oleksik A, Lu Y, Harper K, Lips P. Bone histomorphomet-ric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 2002;17: 341-348.
12. Thiebaud D, Secrest RJ. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. Reprod Fertil Dev 2001;13:331-336.
13. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-1213.
14. Jacobsen DE, Samson MM, Schouw YT, Grobbee DE, Verhaar HJJ. Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women Q70 years: study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial. Trials 2008;9:32.
15. Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985;112:201-210.
16. Deelman BG, Brouwer WH, Zomeren AHV, Saan RJ. Functiestoornis-sen na trauma capitis. In: Jennekens-Schinkel A, Diamant JJ, Diesfeldt HFA, Haaxma R, eds. Neuropsychologie in Nederland. Deventer, the Netherlands: Van Loghum Slaterus, 1980, p 533.
17. Rey A. L'examem psychologique dans les cas d'encephalopathie traumatique. Paris, France: Presses Universitaires de France, 1964.
18. Reitan RM. The relation of the trailmaking test to organic brain damage. J Consult Psychol 1958;19:393-395.
19. Reitan RM. Validity of the trailmaking test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
20. Hunter MS. Psychological and somatic experience of the menopause: a prospective study. Psychosom Med 1990;52:357-367.
21. Hunter M, Battersby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas 1986;8:217-228.
22. EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
23. Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53-72.
24. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-741.
25. Sheikh G, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: Haworth Press, 1986:165-173.
26. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
27. Spielberger CD. The measurement of state and trait anxiety: conceptual and methodological issues. In: Levi LC, ed. Emotions: Their Parameters and Measurement. New York, NY: Raven Press, 1995:713-725.
28. Ploeg van der HM. De Zelf-Beoordelings Vragenlijst (STAI-DY). Tijdschr voor Psychiatrie 1982;24:576-588.
29. Strickler R, Stoval DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy post-menopausal women: a placebo-controlled randomized trial. Obstet Gynaecol 2000;96:359-365.
30. Nilsen J, Mor G, Naftolin F. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 1998;5:211-216.
31. Wu X, Glinn MA, Ostrowski NL, et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 1999;847:98-104.
32. O'Neill K, Chen S, Diaz Brinton R. Impact of the selective estrogen receptor modulator, raloxifene on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004;185:63-80.
33. Lee CC, Kasa-Vubu JZ, Supiano MA. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. J Am Geriatr Soc 2003;51:683-688.
34. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 2002;287:847-857.
35. Shah S, Bell RJ, Davis SR. Homocysteine, estrogen and cognitive decline. Climacteric 2006;9:77-87.
36. Nijland EA, Weijmar Schultz WCM, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 2007;58:164-173.